Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amcad BiomedROCO:4188 -0.32%53 PB Ratio is 1.15 as of Aug. 02, 2026, which is 49% below its 10-year median of 2.25. GuruFocus rates ROCO:4188 with a GF Score™ of 53/100 and a GF Value™ of NT$9.10 (Fairly Valued). The stock has 4 warning signs investors should review. Among 787 Medical Devices & Instruments companies, Amcad Biomed ranks better than 73.7% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-02), Amcad Biomed's share price is NT$9.45. Amcad Biomed's Book Value per Share for the quarter that ended in Dec. 2025 was NT$8.23. Hence, Amcad Biomed's PB Ratio of today is 1.15.
Good Sign:
Amcad Biomed Corp stock PB Ratio (=1.23) is close to 10-year low of 1.19.
The historical rank and industry rank for Amcad Biomed's PB Ratio or its related term are showing as below:
ROCO:4188'
s PB Ratio Range Over the Past 10 Years
Min: 1.16 Med: 2.25 Max: 4.89
Current: 1.16
During the past 13 years, Amcad Biomed's highest PB Ratio was 4.89. The lowest was 1.16. And the median was 2.25.
ROCO:4188's PB Ratio is ranked better than 73.7% of 787
companies
in the Medical Devices & Instruments industry
Industry Median: 2.05
vs ROCO:4188: 1.16
During the past 12 months, Amcad Biomed's average Book Value Per Share Growth Rate was -8.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 1.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -1.70% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -3.40% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Amcad Biomed was 82.70% per year. The lowest was -8.60% per year. And the median was 1.10% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Amcad Biomed PB Ratio Related Terms
Amcad Biomed PB Ratio Historical Data
* Premium members only.
The historical data trend for Amcad Biomed's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Amcad Biomed's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amcad Biomed PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Amcad Biomed's PB Ratio distribution charts can be found below:
* The bar in red indicates where Amcad Biomed's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Amcad Biomed's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Amcad Biomed (ROCO:4188) has a PB Ratio of 1.15 as of Aug. 02, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Amcad Biomed and its competitors. This is 49% below median its historical median of 2.25. Over the past decade, Amcad Biomed's PB Ratio has ranged from 1.16 to 4.89. According to the industry distribution chart, Amcad Biomed ranks #207 out of 787 companies in the Medical Devices & Instruments industry, placing it in the top 26.3%.
Is Amcad Biomed's PB Ratio too high?
Amcad Biomed's current PB Ratio of 1.15 is 49% below median its 10-year median of 2.25. Over the past 10 years, this metric has ranged from a low of 1.16 to a high of 4.89. The Medical Devices & Instruments industry median PB Ratio is 2.05. Amcad Biomed's value of 1.15 is 43.9% below this industry median. Based on the distribution chart, Amcad Biomed ranks #207 out of 787 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Amcad Biomed has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Amcad Biomed's PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Amcad Biomed ranks #207 out of 787 companies for PB Ratio. This puts Amcad Biomed in the upper half of its industry. The industry median PB Ratio is 2.05. Amcad Biomed's value of 1.15 is 43.9% below this benchmark. Historically, Amcad Biomed's own PB Ratio has ranged from 1.16 to 4.89 over the past decade. While the company's 10-year median is 2.25 vs. the industry median of 2.05, Amcad Biomed has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.05, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amcad Biomed's current PB Ratio of 1.15 is 43.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Amcad Biomed and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amcad Biomed's current PB Ratio is 1.15, which is 49% below median its own 10-year median of 2.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amcad Biomed stock overvalued right now?
Based on GuruFocus' analysis, Amcad Biomed (ROCO:4188) is currently considered Fairly Valued. The stock's GF Value™ is NT$9.10, compared to a current price of NT$9.45 — trading 3.8% above its estimated fair value. The current PB Ratio is 1.15, which is 49% below median its 10-year median of 2.25 and 43.9% below the Medical Devices & Instruments industry median of 2.05. Amcad Biomed's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Amcad Biomed (ROCO:4188), the current PB Ratio is 1.15 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amcad Biomed (ROCO:4188) Overvalued in 2026?
Based on GuruFocus' analysis, Amcad Biomed stock appears to be overvalued.
The current stock price of NT$9.45 is trading 3.8% above its estimated GF Value™ of NT$9.10.
GuruFocus considers Amcad Biomed to be Fairly Valued.
Key valuation signals for ROCO:4188:
PB Ratio: 1.15 (49% below median its 10-year median of 2.25)
GF Value™: NT$9.10 vs. price of NT$9.45 (3.8% above fair value)
Industry Position: 43.9% below the Medical Devices & Instruments median (#207 of 787)
No single metric tells the full story. See the ROCO:4188 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amcad Biomed Corp develops computer-aided detection and diagnosis(CADe/CADx) software devices. Its product pipeline includes AmCAD-UT Detection, AmCAD-UV, AmCAD and AmCAD-UO. Geographically, the company generates revenue from Taiwan, China, Europe, Asia (excluding Taiwan and China), and other countries, out of which the majority of the revenue is generated from Taiwan. The company has two segments: the Medical Diagnostic Software segment, which is responsible for the development and sales of smart medical imaging diagnostic software devices, and the Precision Medical Equipment segment, which is responsible for research, development, manufacturing, and sales of high-end ultrasonic probes. The company generates the majority of its revenue from the Precision Medical Equipment segment.
53GF Score
Get the complete analysis for ROCO:4188
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4188 has been successfully added to your 
